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repeat-PCI (1% vs 2.7 %, p = 0.005), need for urgent CABG (0.1% vs 1.3 %, p = 0.03),
seven months MACE (1% vs 3.1 %, p = 0.029), seven months TVR (11 % vs 19.9%, p =
0.001), combined MACE /TVR at seven months (14.9 % vs 26.9 %, p = 0.001) and death
at seven months (1 % vs 3.1 %, p = 0.029).
Conclusion: Analysis of our large database of bifurcation lesions shows that provisional
T stenting is the sole modifiable predictor associated with a reduction in target vessel
revascularization as well as MACE and should be the preferred strategy for coronary
bifurcation lesion PCI.
11:45 a.m.
878-6 Stenting Under Intravascular Ultrasound Guidance of 
Coronary Bifurcation Lesions With a New Device 
Allowing Provisional Side Branch Treatment
Wim J. Vander Giessen, Jurgen R. Ligthart, Pieter C. Smits, Pim J. de Feyter, George 
Sianos, Thierry Lefèvre, Patrick W. Serruys, Thoraxcenter, Erasmus MC, Rotterdam, The 
Netherlands
Background: A new stent (MULTI-LINK FRONTIER) was developed for coronary bifur-
cation lesions. It is an 18 mm stent premounted on a delivery system with 2 balloons. The
device is positioned by pushing it up to the carina of the bifurcation. Simultaneous infla-
tion of the balloons deploys the main branch (MB) stent and opens up a portal to the side
branch (SB). We studied intravascular ultrasound (IVUS) parameters and their relation to
procedural success and 6-month outcome.
Methods: Patients with (un)stable angina pectoris and de novo or restenotic (no previous
stent) bifurcation lesion between 2.5 and 4 mm in diameter for the main branch and
>2.0mm for the side branch were eligible. Exclusion criteria were angiographic severe
calcification, thrombus or left main lesion. Pre-, post-, and at follow-up IVUS was per-
formed in MB and SB using a 30 MHz catheter and automated pull-back.
Results: 18 patients were included: male 14, age 62 (13) year. The LAD/diag bifurcation
was the target lesion in 17/18. After IVUS and mandatory predilatation stent implantation
was successful in 16 (89%). Failure to wire the SB or to position the catheter in phase
with the SB were the cause. Implantation at the carina succeeded in 12/16 (75%). The
cases with ”carina failure” had longer segments with calcified plaque proximal to the car-
ina than cases with “carina success” (25 (14) vs 11 (11) mm; P<0.05) as assessed by
IVUS. The presence of calcium per se, or its circumferential angle or whether superficial
or deep was not associated with carina failure. Carina failure resulted in (partial) overlap
of the stent with the ostium of the SB in 75%. Carina failure or SB overlap was not asso-
ciated with SB restenosis. MLA by IVUS pre-, post-, and at 6 months FU was 2.3 (1.2)
mm2, 7.3 (2.2) mm2, and 4.2 (1.0) mm2, resp. (P<0.05). At FU there were no deaths or
MI’s. Target vessel revascularization occurred in 3 patients (16.6%). Angiographic rest-
enosis (>50% DS) occurred in 18.8% in the Frontier stent MB and in 12.5% in the SB,
overall 31.3%.
Conclusion: This bifurcation stent can be implanted in about 90% of lesions, with prom-
ising 6 months adverse event rate. Longer proximal calcified segment is associated with
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880-1 Repeat Intracoronary Gamma Radiation for Patients 
With In-Stent Restenosis Who Failed Radiation 
Therapy: Results From the Re-WRIST Clinical Trial
Ron Waksman, Andrew E. Ajani, Rebecca Torguson, Donna J. Whitman, Daniel A. 
Canos, Regina Deible, Lowell F. Satler, William O. Suddath, Augusto D. Pichard, Kenneth 
M. Kent, Joseph Lindsay, Washington Hospital Center, Washington, DC
Background: Intracoronary radiation (IR) is an effective therapy for preventing the recur-
rence of in-stent restenosis (ISR). However, nearly 20% of patients enrolled in radiation
studies required repeat revascularization to the irradiated site. Re-WRIST is a registry
evaluating the safety and efficacy of retreatment with IR.
Methods: Thirty pts (31 lesions) with ISR at the previously irradiated segment and who
failed a subsequent angioplasty without radiation were eligible for retreatment with IR.
The Checkmate radiation system using Ir-192 seeds was udes, and the repeat was pre-
scribed dose was 15 Gy at 2 mm. The antiplatlet regimen post procedure was lifelong
aspirin and at least 6 months of clopidogrel.
Results: Pts mean age was 65±7.9 yrs, 67% were males, 52% were diabetic, and 90%
had CABG. Lesions were in native coronaries 67.7%, saphenous vein grafts 29.0%, and
the left internal mammary 3.3%. Time between radiation treatments was 16.4±8.7 mos
and the number of interventions to the target lesion was 5.2±3.5 (range 3-20). The lesion
length was 21.74±14.25 mm. At 9 mos, the major adverse cardiac events rate was 36%,
target lesion revascularization 32%, MI 0%, and deaths 4%. QCA at 9 months demon-
strated a restenosis rate of 35%. There was one late total occlusion and no angiographic
complications (evidence of aneurysm, fibrosis, perforation) in any of the pts.
Conclusions: Repeat radiation to the same site using Ir-192 for refractory ISR is safe
and should be considered an option in this difficult patient subset. 
10:45 a.m.
880-2 Randomized Comparison of Rotational Atherectomy 
and Cutting Balloon Angioplasty Followed by Radiation 
Therapy With a 188Re-MAG3-Filled Balloon in the 
Treatment of Diffuse In-Stent Restenosis
Seong-Wook Park, Seung-Whan Lee, Young-Hak Kim, Ki-Hoon Han, Cheol Whan Lee, 
Myeong-Ki Hong, Jae-Joong Kim, Seung-Jung Park, Asan Medical Center, Seoul, South 
Korea
Background: Randomized comparison of rotablation atherectomy (RA) and cutting bal-
loon angioplasty (CB), followed by beta-radiation for in-stent restenosis (ISR) has not
been reported.
Methods: This randomized controlled study was conducted to compare the efficacy of
RA (n=58) with CB (n=55) prior to beta-radiation therapy with a rhenium-188-mercap-
toacetyltriglycine (188Re-MAG3)-filled balloon for diffuse in-stent restenosis (ISR). The
radiation dose was 18 Gy at a depth of 1.0 mm into the vessel wall.
Results: The baseline clinical and angiographic characteristics were similar between the
2 groups. The lesion length was 21.0±11.2 mm in the RA group and 20.8±10.2 mm in the
CB group (p=0.77). Radiation was delivered successfully to all patients. Adverse events
including myocardial infarction, death, or stent thrombosis did not occurred during the 9-
month follow-up period. Six months angiographic follow-up was obtained in 88 patients
(78%) and the rates of angiographic restenosis was not statistically different between the
RA group (13%, 6/46) and the CB group (12%, 5/42)(p=0.87). The risk of a target lesion
revascularization or a major adverse cardiac event was similar between two groups (RA
group vs CB group: 3.4% vs 3.6%, p=0.94) during 9-month follow-up period.
Conclusions: Concomitant treatment of RA or CB with beta-irradiation using a 188Re-
MAG3-filled balloon for diffuse ISR was safe and had a similarly favorable angiographic
and clinical outcomes.
11:00 a.m.
880-3 Histopathological Characteristics of Edge Restenosis 
After Intracoronary Brachytherapy for In-Stent 
Restenosis
Masaharu Okada, Hideo Tamai, Eisho Kyo, Kunihiko Kosuga, Tatsuhiko Hata, Takuji 
Nakamura, Shinya Fujita, Takafumi Tsuji, Shinsaku Takeda, Nobutoyo Masunaga, 
Katsuyuki Hasegawa, Seiichiro Motohara, Hiromu Uehata, Shiga Medical Center for 
Adults, Moriyama, Japan
Background: Histopathology of edge restenosis following intracoronary brachytherapy
(BT) has not been fully evaluated in humans. The purpose of this study was to clarify the
histopathological characteristics of edge restenosis following BT by examining the speci-
mens obtained from directional coronary atherectomy (DCA). Methods: Eight edge rest-
enosis lesions which developed in native coronary arteries after BT with the beta-emitting
32P source wire were obtained by DCA and were compared with the restenosis lesion
which developed after ordinary balloon angioplasty without BT (R, 6 lesions). Edge rest-
enosis was defined as a lesion which developed 5 mm proximal or distal to either edge of
32P source wire. Mean interval from BT to edge restenosis was 242±28 days. Specimens
retrieved by DCA were immediately placed in 10% buffered formalin, processed for paraf-
fin embedding and stained with hematoxylin and eosin. To assess the proliferation of
myofibroblast, we categorized the severity as grade 0, 1, 2, and 3 by estimating the cell
density and analyzed by Mann-Whitney U test. Results: 1) Invasion of inflammatory cells
and evidence of vasculitis were not apparent in any of the edge restenosis lesions or R
lesions. 2) In edge restenosis lesions, myofibroblasts were more scarce and active prolif-
Baseline (post procedure) Follow up (9 months)
RVD, mm 2.66+/-0.57 2.62+/-0.58
MLD, mm 2.07+/-0.66 1.61+/-0.98
DS, % 23.53+/-10.5 38.4+/-36.33
In-stent MLD, mm 1.99+/-0.56 1.23+/-0.76
In-stent DS, % 27.75+/-8.48 51.66+/-33.2
In-lesion late loss, mm 0.51+/-0.99
Binary Restenosis, % 35
MLD:minimal lumen diameter
RA group CB group P value
Pre MLD (mm) 0.76±0.37 0.84±0.41 0.30
Post MLD (mm) 2.59±0.39 2.69±0.53 0.30
Follow-up MLD (mm) 2.01±0.66 2.22±0.68 0.15
Acute gain (mm) 1.79±0.54 1.85±0.60 0.58
Late loss (mm) 0.35±0.52 0.54±0.60 0.25
Loss index 0.19±0.36 0.29±0.36 0.34




















eration was less evident than R lesions (grade;1.13±0.35 vs 2.17±0.75; P<0.01). 3) In
edge restenosis lesions, extracellular matrices were abundant, and they were composed
of coarse collagen fiber and abundant mucinous materials. In contrast, the major compo-
nent of extracellular matrices in the R lesions were finely fibrillar and dense collagen. 4)
Thrombi were not apparent in any edge restenosis or R lesions. Conclusions: Edge res-
tenosis following BT consisted of weak proliferation of myofibroblasts and abundant dep-
osition of extracellular matrices such as mucinous materials. It was not be accompanied
by inflammatory reaction or thrombosis. Edge restenosis following BT may be a patholog-
ically distinct entity.
11:15 a.m.
880-4 Intracoronary Brachytherapy Protects Bifurcation 
Lesions
Karsten Meyer, Ralf Koester, Jan Kaehler, Andreas Schuchert, Horst Thurmann, Manuel 
Todorovic, Winfried Alberti, Thomas Muenzel, Thomas Meinertz, Andreas Kruell, 
University of Hamburg, Hamburg, Germany
Background: Intracoronary brachytherapy frequently involves lesions from which side
branches originate. These side branches often contain proximal plaques raising the
question whether a bifurcation intervention is required. To date it is not clear whether
plaque progression at the origin of the side branch is arrested by the brachytherapy of the
main branch. In this study we analyzed the plaque progression in side branches of
lesions treated with intracoronary brachytherapy.
Methods: One hundred and fourty-six patients with in-stent-restenosis >70% in diameter
were treated with PTCA followed by intracoronary brachytherapy. Brachytherapy was per-
formed with the Betacath system (Novoste). Thirty-three patients had bifurcation lesions
involving a side branch of 1.7±0.4 mm in diameter, originating from the irradiated portion
of the LAD (n=20), LCX (n=5) or RCA (n=8). Five lesions in side branches were dilated
during bifurcation interventions. Brachytherapy was performed with 18.5±1.5 Gy for
199±35 seconds within the main vessel but not in the side branch. The lumen diameter of
the side branch was analyzed by quantitative coronary angiography (QCA) at the time of
intervention and at follow-up at 8.6±3.5 months.
Results: There was one asymptomatic side branch occlusion due to the procedure.
There were no in-hospital adverse events such as death, myocardial infarction or reinter-
vention. QCA revealed a side branch minimal lumen diameter of 1.3±0.6 mm at the time
of intervention and of 1.4±0,7 mm at follow-up corresponding to mean diameter stenoses
of 25.2±22.9% and 24.7±23.1% (p>0.05). At follow-up none of the dilated side branch
lesions had a binary diameter restenosis (>50%). There was no further side branch
occlusion and no adverse clinical event related to the side branch lesion.
Conclusion: Intracoronary brachytherapy appears to have a protective effect on the pro-
gression of lesions in side branch origins even if brachytherapy is only performed in the
main branch and not in the side branch.
11:30 a.m.
880-5 Optimizing Dosimetry With High Dose Intracoronary 
Gamma Radiation 21 Gy for Patients With Diffuse In-
Stent Restenosis
Ron Waksman, Rebecca Torguson, Ellen Pinnow, Donna J. Whitman, Afework 
GebreEyesus, Rosanna Chan, Eduard Cheneau, Andrew E. Ajani, Michael Porrazzo, 
Lowell F. Satler, Augusto D. Pichard, Kenneth M. Kent, Joseph Lindsay, Washington 
Hospital Center, Washington, DC
Background: The efficacy of coronary gamma radiation in preventing recurrent in-stent
restenosis (ISR) is established. Vascular brachytherapy (VBT) may be less effective with
the approved dose of 14 Gy. Previously we reported a better outcome with 18 Gy. We
sought to examine if escalation of the dose to 21 Gy is safe and improves efficacy.
Methods: 35 pts with diffuse ISR in native coronary arteries and saphenous vein grafts
(lesion length 20-80mm) underwent PCI, atherectomy, and/or additional stents. Post-
intervention pts were treated with gamma VBT using the Checkmate system (Cordis). A
ribbon with 14-23 seeds was positioned to cover the treated segment and adequate mar-
gins, with a mean length of 63 ± 8mm. The prescribed dose was 21 Gy at 2mm. All pts
were discharged with Clopidogrel for 12 mo. 6-mo clinical outcomes were compared to
120 pts treated with 14 Gy and 120 pts treated with 18 Gy, both groups treated with at
least 6 mo of Clopidogrel. 
Results: High dose of 21 Gy was associated with prolonged dwell time of 28.6 + 2.9 min,
but with absence of procedural or in-hospital complications, when compared with lower
doses. At 6 mo there was significant reduction in the need for repeat target lesion revas-
cularization in the pts treated with 21 Gy (Table) 
Conclusions: High dose of 21 Gy for patients undergoing VBT with gamma radiation is
associated with less recurrences compared to the approved radiation dose without
increase of adverse events. Thus, optimization of the dose should be considered for pts
undergoing VBT for ISR.
11:45 a.m.
880-6 Three-Year Follow-Up After Intracoronary Gamma 
Radiation for In-Stent Restenosis in Saphenous Vein 
Grafts
Seung-Woon Rha, Ron Waksman, Pramod K. Kuchulakanti, Andrew E. Ajani, Larry R. 
White, Daniel A. Canos, Edouard Cheneau, Verne Mattox, Maureen C. Abbott, Ellen 
Pinnow, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, 
Washington Hospital Center, Washington, DC
Background: The Washington Radiation for In-Stent Restenosis Trial in saphenous vein
grafts (SVG WRIST) demonstrated safety and efficacy of intracoronary gamma radiation
for the treatment of in-stent restenosis (ISR) in saphenous vein grafts (SVG) at 6 months.
The aim of this study was to examine whether the results reported at 6 months continued
to be durable at 36 months.
Methods: One hundred and twenty patients (pts) with ISR in SVG underwent PTCA,
laser ablation, rotational atherectomy, and/or additional stenting (36% of lesions). Pts
were randomized to either 192Ir IRT or placebo, with a prescribed dose of 15 Gy or 18 Gy
to a 2 mm radial distance from the center of the source. Pts were followed angiographi-
cally at 6 months and clinically up to 36 months.
Results: Angiographic restenosis (21 %vs. 44%, p=0.005) and target vessel revascular-
ization [TVR, (18 % vs. 55%, p<0.001)] were dramatically reduced at 6 months in intrac-
oronary radiation therapy (IRT) pts. At 12 months, IRT compared to placebo pts had less
target lesion revascularization [TLR, (17% vs.57%, p<0.001)] and TVR (28% vs. 62%,
p<0.001). At 36 months clinical follow-up, pts receiving IRT continued to have markedly
lower MACE rates when compared with controls (Table).
Conclusions: In SVG WRIST, pts with ISR treated with IRT using 192Ir had a marked
reduction in the need for repeat target lesion and vessel revascularization at 6 months,
with durability of the clinical benefit at three years.













Death, % 0 1.7 0 0 0 0
Q-Wave 
MI, %
0 0.8 0 0.9 0 0
TLR, % 0.8 20.8 2.5 16.5 0 8.3
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Death 7 7 1.0 17 10 0.283
Q-wave 
MI
2 3 1.0 3 2 0.559
TVR 28 62 <0.001 47 65 0.043
TLR 17 57 <0.001 33 60 0.003
All MACE 23 57 <0.001 38 63 0.006
